Monthly report on application procedures, guidelines and related documents for veterinary medicines
|
|
- Tabitha Harvey
- 5 years ago
- Views:
Transcription
1 2 June 7 EMA/3737/7 Veterinary Medicines Division Monthly report on application procedures, guidelines and related documents for May 7 This report, which is updated every month, provides current information related to the volume and evaluation of pre- and post-authorisation applications for medicinal products for veterinary use received by the European Medicines Agency (EMA) for the current and previous three years on: scientific advice requests; applications for initial evaluations, extensions, variations and renewals concerning marketing authorisations (MAs); applications for initial evaluations, extensions, modifications and extrapolations for maximum residue limits (MRLs); arbitration and referral procedures; requests for classification and re-classifications of products as Minor Use Minor Species (MUMS)/limited market. In addition, the report includes a summary table of the opinions issued by the Committee for Medicinal Products for Veterinary Use (CVMP) in the current year, as well as a list of adopted guidelines and other public guidance documents. The purpose is only to provide ongoing factual information. Commentaries and analysis are provided in the Agency's annual reports. 3 Churchill Place Canary Wharf London E4 EU United Kingdom Telephone +44 () Facsimile +44 () 366 Send a question via our website An agency of the European Union European Medicines Agency, 7. Reproduction is authorised provided the source is acknowledged.
2 Statistics on pre- and post-authorisation applications for medicinal products for veterinary use Scientific advice requests Submitted and validated Advice given Scientific advice requests submitted and advice given Submitted Advice given 9 8 Initial evaluation of marketing authorisation applications Full (submitted) Abridged/generics (submitted) 4 3 Withdrawals 3 Positive opinions 4 7 Negative opinions Pre-authorisation: submissions of MA applications by type Pre-authorisation: outcome of the evaluation of MA applications Full (submitted) Abridged/generics (Submitted) Positive opinions Negative opinions EMA/3737/7 Page 2/
3 Marketing authorisations Granted Withdrawals 3 Refusal Not renewed Extensions applications Submitted Withdrawals Positive opinions 2 6 Negative opinions Variations applications submitted 4 6 Type-IA variations Type-IB variations Type-II variations Transfers Post-authorisation: submissions of variations and transfers Type IA variations Type IB variations Type II variations Transfers Renewals applications Submitted 24 3 Positive opinions 9 4 Negative opinions EMA/3737/7 Page 3/
4 Establishment of MRLs for new substances applications Submitted Withdrawals 2 Positive opinions 2,3 4 3 () 2 2 Negative opinions Extensions/modifications of MRLs 4 applications Submitted Withdrawals Positive opinions Negative opinions Review of opinions/extrapolations of MRLs requests from Commission or Member States Submitted 2 Opinion Substances considered as not falling within the scope of Regulation (EC) No 47/9 requests Submitted Agreed Not agreed 2 Scientific advice recommended MRL-related submissions New applications Extensions/modifications Review/extrapolations Out of scope Establishment of MRLs for new substances under article 3 of Regulation (EC) No 47/9. 2 Including opinions recommending the extension of the expiry date for provisional MRLs or definitive MRLs for substances previously with provisional MRLs. 3 Re-examinations of opinions are indicated in brackets. 4 Extension or modification of MRLs under article 3 of Regulation (EC) No 47/9. Review of opinions under article of Regulation (EC) No 47/9 or requests under article 27 of Regulation (EC) No 47/9. EMA/3737/7 Page 4/
5 MUMS/limited market (re)classification requests outcome MUMS/limited market with financial incentives MUMS/limited market without financial incentives MUMS/limited market reclassification with financial incentives 6 MUMS/limited market reclassification without 3 2 financial incentives 6 Not MUMS/limited market Outcome of MUMS/limited market (re-)classification requests MUMS with financial incentives MUMS without financial incentives Not MUMS Re-classification with incentives Re-classification without incentives Arbitrations and referrals Arbitrations and referrals submitted Opinions 7 () 7 4() Arbitrations and referrals submitssions and opinions Referrals submitted Opinions and re-examinations 6 For re-classification the first year available is 4. 7 Re-examinations of opinions are in brackets. EMA/3737/7 Page /
6 CVMP opinions in 7 on medicinal products for veterinary use Positive opinions Product Invented name INN/Common name Credelio Lotilaner CYTOPOINT Lokivetmab Zulvac BTV Ovis Bluetongue vaccine (inactivated) (multistrain: -2 strains out of a set of 3) Ingelvac PCV FLEX Porcine circovirus vaccine (inactivated) RESPIPORC FLUpan HN Swine influenza vaccine (inactivated) Zeleris Florfenicol/meloxicam Prevomax Maropitant Marketing Target species Regulatory information authorisation holder Procedure number Opinion date Elanco Europe Ltd Dog EMEA/V/C/4247/ 6/2/7 Zoetis Belgium SA Dog EMEA/V/C/3939/ 6/2/7 Zoetis Belgium SA Sheep EMEA/V/C/48/ 6/2/7 Boehringer Pig EMEA/V/C/464/ Ingelheim 6/3/7 Vetmedica GmbH IDT Biologika Pig EMEA/V/C/3993/ GmbH 6/3/7 CEVA Santé Cattle EMEA/V/C/499/ Animale 6/3/7 Le Vet Beheer B.V. Dogs, Cats EMEA/V/C/433/ 2/4/7 EMA/3737/7 Page 6/
7 CVMP opinions in 7 on establishment of MRLs Positive opinions Product Target species Regulatory information Substance Procedure number Opinion date Alarelin All food producing species EMEA/V/MRL/476/FULL/ 2/4/7 Bromelain Porcine EMEA/V/MRL/4479/FULL/ //7 EMA/3737/7 Page 7/
8 Arbitrations and referrals in 7 Ongoing procedures Type of procedure Date Clock start CVMP opinion Product Product name INN 34 of Directive /82/EC 3 of Directive /82/EC 3 of Directive /82/EC (re-examination) 3 of Directive /82/EC 3 of Directive /82/EC 34 of Directive /82/EC 34 of Directive /82/EC 3 of Directive /82/EC 9/9/ Denagard 4% and associated names 2/4/7 Tiamulin hydrogen fumarate // All veterinary medicinal products //7 containing moxidectin to be administered to cattle, sheep and horses Moxidectin 7/2/6 All veterinary medicinal products 8/2/6 containing zinc oxide to be 6/3/7 administered orally to food producing species Zinc oxide 8//6 Veterinary medicinal products 6/3/7 containing methylprednisolone hydrogen succinate presented as solutions for injection for intramuscular use in cattle Methylprednisolone hydrogen succinate 3/7/6 Veterinary medicinal products 6/3/7 containing tylosin to be administered parenterally and intended for the treatment of bovine mastitis caused by Mycoplasma spp Tylosin 3/7/6 Girolan and its associated name Apralan Apramycin sulfate 3/7/6 Lincocin and associated names Lincomycin 7/9/6 Zanil and associated names, and generic products thereof Oxyclozanide EMA/3737/7 Page 8/
9 Guidelines and working documents in 7 CVMP quality EMA/CHMP/CVMP/QWP/BWP/42 83/6 EMA/CHMP/CVMP/QWP/82677/ 6 Draft Concept paper on the need for Revision of Note for guidance on quality of water for pharmaceutical use (H+V) Corrigendum to Reflection paper on the Requirements for selection and justification of starting materials for the manufacture of chemical active substances Adopted for consultation January 7 (End of consultation TBC) Adopted January 7 CVMP safety EMA/CVMP/SWP/37724/6 Guideline on assessment and control of DNA reactive (mutagenic) impurities in veterinary medicinal products Adopted for consultation February 7 (End of consultation 3 August 7) CVMP efficacy EMA/CVMP/344/999-Rev.2 EMA/CVMP/EWP/7336/3 EMA/CVMP/EWP/6/-Rev.3 Guideline on the conduct of efficacy studies for intramammary products for use in cattle Reflection paper on anthelmintic resistance Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products Adopted January 7 Adopted April 7 Adopted for consultation April 7 (End of consultation 3 October 7) CVMP pharmacovigilance EMA/CVMP/PhVWP/722/6 Revised recommendation for the basic surveillance of Eudravigilance Veterinary (EVVet) data for centrally authorised products (CAPs) Adopted for consultation February 7 (End of consultation 3 August 7) EMA/3737/7 Page 9/
10 EMA/CVMP/PhVWP/33762/2 - Rev. EMA/CVMP/PhVWP/3739/ Revised Questions and answers on serious non-fatal adverse events and reporting rules Reflection paper on nonspontaneous adverse event reports (literature, internet and social media) for veterinary medicinal products Adopted April 7 Adopted May 7 CVMP antimicrobials CVMP immunologicals EMA/CVMP/IWP/9262/4 EMA/CVMP/IWP/23243/6- Rev.3 CVMP Risk Management Strategy - Managing the risk of the potential presence of replication competent endogenous retrovirus RD4 in starting materials and final products of feline and canine vaccines Guideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market Adopted February 7 Adopted April 7 CVMP environmental risk assessment EMA/CVMP/ERA/3/ EMA/CVMP/ERA/6894/ EMA/CVMP/4482/ Guideline on assessing the toxicological risk to human health and groundwater communities from veterinary pharmaceuticals in groundwater Guideline on the plant testing strategy for veterinary medicinal products Authorisation of veterinary medicinal products containing (potential) persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vpvb) substances Adopted for consultation February 7 (End of consultation 3 August 7) Adopted March 7 Adopted April 7 EMA/3737/7 Page /
11 CVMP novel therapies Replacement, Reduction, Refinement of animal testing (3Rs) General EMA/CVMP/7793/6 Question and answer on the information contained within section. of the SPC on pharmacodynamic properties for pharmaceutical products Adopted February 7 EMA/3737/7 Page /
Committee for Medicinal Products for Veterinary Use
20 April 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management Monthly report of application procedures, guidelines and related documents April 2011 The CVMP monthly report includes
More informationCVMP Monthly report of application procedures, guidelines and related documents
8 July 2013 EMA/249895/2013 Committee for Medicinal Products for Veterinary Use (CVMP) CVMP Monthly report of application procedures, guidelines and related documents June 2013 The CVMP monthly report
More informationCommittee for Medicinal Products for Veterinary Use
5 November 2010 EMA/CVMP/649372/2010 Veterinary Medicines and Product Data Management Monthly report of application procedures, guidelines and related documents October 2010 The CVMP monthly report includes
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Meeting of December 2016
09 EMA/794393/2016 Press Office Press release Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 06-08 CVMP opinions on veterinary medicinal products The Committee adopted by consensus
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Meeting of July 2016
15 July EMA/CVMP/454098/ Press Office Press release Committee for Medicinal Products for Veterinary Use (CVMP) Meeting of 12-14 July The Committee elected Helen Jukes from the United Kingdom as its vice-chair
More informationCommittee for Medicinal Products for Veterinary Use
4 July 2011 EMA/CVMP/37837/2011 Veterinary Medicines and Product Data Management Monthly report of application procedures, guidelines and related documents June 2011 The CVMP monthly report includes statistical
More informationCommittee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018
7 December 2017 Committee for Medicinal Products for Veterinary Use (CVMP) Committee for Medicinal Products for Veterinary Use (CVMP) Work Plan 2018 Chairpersons Chair: D. Murphy Status Adopted in December
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE. Monthly Report of Application Procedures, Guidelines and Related Documents
European Medicines Agency Veterinary Medicines and Inspections London, 30 April Doc. Ref. EMEA/284966/ COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Monthly Report of Application Procedures, Guidelines
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections London, 20 June 2003 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS Meeting of 17 to 19 June
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE. Monthly Report of Application Procedures, Guidelines and Related Documents
European Medicines Agency Veterinary Medicines and Inspections London, 30 November 2007 Doc. Ref. EMEA/571778/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Monthly Report of Application Procedures,
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004
European Medicines Agency Veterinary Medicines and Inspections London, 16 July 2004 EMEA/CVMP/713/04/Rev 1 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 13 to 15 July 2004
More informationGuideline on quality data requirements for veterinary medicinal products intended for minor use or minor species (MUMS)/limited market
8 December 2016 EMA/CVMP/QWP/128710/2004-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on quality data requirements for veterinary medicinal products intended for minor use
More informationStandard operating procedure
Standard operating procedure Title: Annual review of VeDDRA list to be used in EudraVigilance Veterinary Status: PUBLIC Document no.: SOP/V/4019 Lead author Approver Effective date: 15-MAY-15 Name: Raquel
More informationRecommendation for the basic surveillance of Eudravigilance Veterinary data
1 2 3 25 May 2010 EMA/CVMP/PhVWP/471721/2006 Veterinary Medicines and Product Data Management 4 5 6 Recommendation for the basic surveillance of Eudravigilance Veterinary data Draft 7 Draft agreed by Pharmacovigilance
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004
European Medicines Agency Veterinary Medicines and Inspections London, 15 October 2004 EMEA/CVMP/973/04 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 12 to 14 October 2004
More informationEuropean Public MRL assessment report (EPMAR)
18 March 2016 EMA/CVMP/619817/2015 Committee for Medicinal Products for Veterinary Use European Public MRL assessment report (EPMAR) Gentamicin (all mammalian food producing species and fin fish) On 3
More informationCommittee for Medicinal Products for Veterinary Use
9 February 2010 EMA/CVMP/44332/2010 Veterinary Medicines and Product Data Management Monthly report of application procedures, guidelines and related documents November 2009 The CVMP Monthly Report includes
More informationMedicines for bees. Establishment of maximum residue limits. Principles for marketing authorisations
Medicines for bees Establishment of maximum residue limits Principles for marketing authorisations Presented by: Isaura Duarte Head of Animal and Public Health; Veterinary Medicines Sector An agency of
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE. Monthly Report of Application Procedures, Guidelines and Related Documents
European Medicines Agency Veterinary Medicines and Inspections London, 31 October Doc. Ref. EMEA/CVMP/737551/ COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Monthly Report of Application Procedures,
More informationScientific Discussion post-authorisation update for Rheumocam extension X/007
5 May 2011 EMA/170257/2011 Veterinary Medicines and Product Data Management Scientific Discussion post-authorisation update for Rheumocam extension X/007 Scope of extension: addition of 20 mg/ml solution
More informationCVMP activities regarding antimicrobials Ongoing and recent activities
CVMP activities regarding antimicrobials Ongoing and recent activities European Medicines Agency/IFAH-Europe Info Day 2016 Presented by Helen Jukes on 17 March 2016 Chair CVMP Antimicrobials WP An agency
More informationReflection paper on promotion of pharmacovigilance reporting
13 July 2017 EMA/CVMP/PhVWP/390033/2014-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on promotion of pharmacovigilance reporting Draft agreed by CVMP Pharmacovigilance
More informationMAXIMUM RESIDUE LIMITS FOR VETERINARY MEDICINAL PRODUCTS
SME WORKSHOP 2 February 2007 Jordi Torren Edo Safety of Veterinary Medicines Agenda Main principle Purpose Annexes Legal basis Procedure Extrapolation Ensuring consumer safety during authorisation of veterinary
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology PRESS RELEASE London, 14 June 2001 corr COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 67th MEETING
More informationEuropean Medicines Agency role and experience on antimicrobial resistance
European Medicines Agency role and experience on antimicrobial resistance Regional Training Workshop on Antimicrobial Resistance (AMR) Responding to the global challenge of AMR threats: toward a one health
More informationOpinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004
11 December 2014 EMA/CVMP/761582/2014 Veterinary Medicines Division EMEA/V/A/107 Opinion of the Committee for Medicinal Products for Veterinary Use pursuant to Article 30(3) of Regulation (EC) No 726/2004
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 37th MEETING Under the chairmanship of Professor
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections London, 12 December 2003 EMEA/CVMP/1129/03 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS Meeting
More informationPRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit London, 11 December 1998 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 38th MEETING Under the
More informationCVMP strategy on antimicrobials
1 2 3 6 November 2015 EMA/CVMP/209189/2015 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 Draft Adoption by CVMP for release for consultation 6 November 2015 Start of public consultation
More informationSpecificities of Products for Veterinary Use
Specificities of Products for Veterinary Use The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations Presented
More informationUnits of measurement for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet)
for animals for the collection of data per animal species: Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet) Data collection on consumption of veterinary antimicrobials in Europe achievements,
More informationQuestions and answers on serious non-fatal adverse events and reporting rules
12 April 2017 EMA/CVMP/PhVWP/303762/2012-Rev.1 Committee for Medicinal Products for Veterinary Use Questions and answers on serious non-fatal adverse events and reporting rules This questions and answers
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationReview of Legislation for Veterinary Medicinal Products Version 2
Position Paper Brussels, 13 April 2012 Review of Legislation for Veterinary Medicinal Products Version 2 Directive 2004/28 entered into force on 1 st May 2004, introducing many improvements for the transparent
More informationEuropean public MRL assessment report (EPMAR)
15 January 2013 EMA/CVMP/914694/2011 Committee for Medicinal Products for Veterinary Use (CVMP) European public MRL assessment report (EPMAR) Fenbendazole (extension to chicken and extrapolation to all
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationLegislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union
Legislation, Registration and Control Procedures for Veterinary Medicinal Products in the European Union David Mackay European Medicines Agency (EMEA) London, UK Legal Framework Medicines control within
More informationESVAC (European Surveillance of Veterinary Antimicrobial Consumption)
ESVAC (European Surveillance of Veterinary Antimicrobial Consumption) Present and future activities 60th Meeting of the EFSA advisory forum Presented J. Torren, Scientific Administrator, Animal and Public
More informationMaximum Residue Limits (MRLs) and Consumer safety. Presented by: Isaura Duarte, European Medicines Agency
Maximum Residue Limits (MRLs) and Consumer safety Presented by: Isaura Duarte, European Medicines Agency Overview Consumer safety and MRLs Procedure for the establishment of MRLs in the EU Data requirements
More information62nd MEETING. New MRLs Annex I Annex II Opinions adopted at this 2 1 meeting. Old MRLs 1 Annex I Annex II Extension of provisional MRLs
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology London, 11th January 2001 PRESS RELEASE COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS 62nd MEETING
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 7-9 November 2006
European Medicines Agency London, 10 November 2006 EMEA/CVMP/430553/2006-Rev.1 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 7-9 November 2006 CVMP Opinions on Veterinary
More informationEuropean public MRL assessment report (EPMAR)
11 November 2013 EMA/CVMP/561830/2010 Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR) Neomycin (including framycetin) (All food producing species) On 29
More informationAmoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate. Amoxicillin trihydrate
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of administration, applicant in the Member States Member State EU/EEA Applicant Name
More informationPublic bulletin - Veterinary pharmacovigilance 2010
10 February 2011 EMA/CVMP/PhVWP/44873/2011 Committee for Medicinal Products for Veterinary Use (CVMP) 1. Introduction This is the 8 th bulletin from the European Medicines Agency on veterinary pharmacovigilance
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections London, 24 February 2009 EMEA/CVMP/PhVWP/253196/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE EMEA PUBLIC BULLETIN 2008 ON VETERINARY
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationAntimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines
Antimicrobial resistance (AMR): Presentation on the joint EMA/EFSA RONAFA opinion Harmonisation of SPCs of antimicrobial veterinary medicines EMA Veterinary Medicines Info Day 16-17 March 2017, London
More informationPRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency London, 14 March 2008 EMEA/CVMP/96162/2008 PRESS RELEASE COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE Meeting of 11-13 March 2008 CVMP Opinions on Veterinary Medicinal
More informationGENERAL CONDITIONS FOR THE MARKETING AUTHORISATION
Metacam 5mg/ml cattle and pigs I BACKGROUND INFORMATION ON THE PROCEDURE 1. Steps taken for the assessment of the product The company Boehringer Ingelheim submitted an application to the EMEA on 10 June
More informationProposal for a Regulation on veterinary medicinal products
Proposal for a Regulation on veterinary medicinal products European Commission Directorate Health and Food Safety Health systems and products Medicinal products - quality, safety and efficacy 24 February
More informationVICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms
12 December 2013 EMA/CVMP/VICH/647/2001 Committee for Medicinal Products for Veterinary Use (CVMP) VICH GL30 on pharmacovigilance of veterinary medicinal products: controlled list of terms Adoption by
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Porcilis ColiClos suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 2 ml
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BLUEVAC BTV8 suspension for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CLYNAV solution for injection for Atlantic salmon 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.05 ml dose
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
19 January 2017 EMA/CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use Guideline on the conduct of efficacy studies for intramammary products for use in cattle Draft agreed by Efficacy
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 February 2016 CVMP/344/1999-Rev.2 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in Draft Draft
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/477/03/Final COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS POSITION PAPER REGARDING AVAILABILITY OF PRODUCTS FOR MINOR USES AND MINOR
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT BTVPUR AlSap 1 suspension for injection for sheep and cattle. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose
More informationLegislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish
Legislation on Veterinary Medicinal Products (VMPs) and legal status of relevant VMPs for anesthesia of finfish Anesthesia of Big Research Fish Bergen, March 6th. 2018 Tonje Høy, DVM, PhD Scientific director,
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYTOPOINT 10 mg solution for injection for dogs CYTOPOINT 20 mg solution for injection for dogs CYTOPOINT 30 mg
More informationRequest for advice on the impact on public health and animal health of the use of antibiotics in animals
Request for advice on the impact on public health and animal health of the use of antibiotics in animals Animal Health Advisory Committee 22 March 2013 Mario Nagtzaam, SANCO D6 Political commitments as
More informationName INN Strength Pharmaceutical form. Distocur Oxyclozanide 34 mg/ml Oral suspension Cattle, sheep
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, applicants/marketing authorisation holders in the Member States 1/16
More informationGuideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances Draft
1 2 3 13 September 2018 EMA/CVMP/383441/2005-Rev.1 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 7 Guideline on the summary of product characteristics (SPC) for veterinary medicinal
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More informationMetacam is an anti-inflammatory medicine used in cattle, pigs, horses, dogs, cats and guinea pigs.
EMA/CVMP/259397/2006 EMEA/V/C/000033 An overview of Metacam and why it is authorised in the EU What is Metacam and what is it used for? Metacam is an anti-inflammatory medicine used in cattle, pigs, horses,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 21 October 2008 EMEA/CVMP/SAGAM/428938/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER ON ANTIMICROBIAL
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationUpdate on European Agencies activities in the field of AMR
Update on European Agencies activities in the field of AMR R. M. Peran (EMA) D. Plachouras (ECDC) P.-A. Belœil (EFSA) European AMR One Health Network Meeting 26 October 2018, 10:00 17:00 Conference Center
More informationCouncil of the European Union Brussels, 17 September 2014 (OR. en) Mr Uwe CORSEPIUS, Secretary-General of the Council of the European Union
Council of the European Union Brussels, 17 September 2014 (OR. en) Interinstitutional File: 2014/0257 (COD) 13289/14 PROPOSAL From: date of receipt: 16 September 2014 To: No. Cion doc.: Subject: AGRILEG
More informationAn agency of the European Union
An agency of the European Union Human medicines in 23 Research and development 473 overall number of scientific advice and protocol assistance requests received in 23
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Panacur AquaSol 200 mg/ml oral suspension for use in drinking water for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationESVAC meeting 3 March, 2017 EMA. Presented by Helen Jukes Co-chair RONAFA group, chair of the CVMP s Antimicrobials Working Party
Joint EMA/EFSA scientific opinion of the RONAFA advisory group on measures to reduce the need to use antimicrobial agents in animal husbandry in the EU ESVAC meeting 3 March, 2017 EMA Presented by Helen
More informationStandard operating procedure
Standard operating procedure Title: Procedure for provision of scientific recommendation on classification of ATMPs Status: PUBLIC Document no.: SOP/H/3309 Lead author Approver Effective date: 13-JUN-16
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationDraft ESVAC Vision and Strategy
1 2 3 7 April 2016 EMA/326299/2015 Veterinary Medicines Division 4 5 6 Draft Agreed by the ESVAC network 29 March 2016 Adopted by ESVAC 31 March 2016 Start of public consultation 7 April 2016 End of consultation
More informationWorkshop on Strengthening livestock health and Veterinary Services. Kiev, 2-3 November 2010 TAIEX, AGR 42266
Workshop on Strengthening livestock health and Veterinary Services Kiev, 2-3 November 2010 TAIEX, AGR 42266 1 Session III: Overview Veterinary Medicines Legislation in the EUROPEAN UNION Nancy De Briyne
More informationSUMMARY OF PRODUCT CHARACTERISTICS
[Version 8.1, 01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS [The following are those items of information required by Article 14 of Directive 2001/82/EC, the Guideline on Summary of the Product Characteristics,
More informationHEALTH & CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH & CONSUMERS DIRECTORATE-GENERAL SANCO D D(2011) 1198550 SUMMARY RECORD OF THE STANDING COMMITTEE ON THE FOOD CHAIN AND ANIMAL HEALTH HELD IN BRUSSELS ON 3 & 4 MAY 2010 (Section
More informationStandard operating procedure
Standard operating procedure Title: QRD post-opinion review of product information for post-authorisation procedures affecting the annexes, excluding Annex II applications Status: PUBLIC Document no.:
More informationVeterinary antimicrobials: state of play and future developments 2013 European Medicines Agency/IFAH- Europe Info Day 7-8 March 2013
Veterinary antimicrobials: state of play and future developments 2013 European Medicines Agency/IFAH- Europe Info Day 7-8 March 2013 Mario Nagtzaam, SANCO D6 Political commitments as to addressing AMR
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Novem 5 mg/ml solution for injection for cattle and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationGiles Davis., BVSc., GPCertSAP,, MRCVS
VETERINARY PHARMACOVIGILANCE IN THE UK Giles Davis., BVSc., GPCertSAP,, MRCVS Head of Pharmacovigilance Unit, Veterinary Medicines Directorate, Woodham Lane, New Haw, Addlestone Surrey, KT15 3LS, United
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
5, % EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2017)3482661-11/07/2017 Director-General Brussels, SANTE/E5/DB/mcd Ares (2017) 3584639 Dear Professor Rasi, Subject: Request
More informationMedicines for Bees An introduction to the subject and aim of the workshop Role of the Agency in the initiative
Medicines for Bees An introduction to the subject and aim of the workshop Role of the Agency in the initiative Presented by: Ifigenia Koudouna Scientific Administrator, Veterinary Medicines Sector European
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT ZACTRAN 150 mg/ml solution for injection for cattle, sheep and pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT VEPURED suspension for injection for pigs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains:
More informationVICH Topic GL20 EFFICACY OF ANTHELMINTICS: SPECIFIC RECOMMENDATIONS FOR FELINE
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology CVMP/VICH/545/00-FINAL London, 30 July 2001 VICH Topic GL20 Step 7 EFFICACY OF ANTHELMINTICS:
More informationDIRECTIVE 2001/82/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to veterinary medicinal products
2001L0082 EN 07.08.2009 004.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/82/EC OF THE EUROPEAN PARLIAMENT
More informationRUMA: Advocating Prudent Use of Antimicrobial Compounds
RUMA: Advocating Prudent Use of Antimicrobial Compounds John FitzGerald Responsible Use of Medicines in Agriculture (RUMA) Alliance Antimicrobial Resistance: A Whole Food Chain Approach How should Ireland
More information1. ABOUT THE CONSULTATION
Better regulation of veterinary pharmaceuticals: how to put in place a simpler legal framework, safeguarding public and animal health while increasing the competitiveness of companies 1. ABOUT THE CONSULTATION
More informationEMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials
EMA advice on the impact of the use of antibiotics on public and animal health: Potential impact on the authorisation of antimicrobials Helen Jukes, CVMP member EMA/IFAH-Europe Info Day, 12 March 2015
More informationCommittee on the Environment, Public Health and Food Safety
EUROPEAN PARLIAMT 2014-2019 Committee on the Environment, Public Health and Food Safety 14.4.2015 2014/0257(COD) ***I DRAFT REPORT on the proposal for a regulation of the European Parliament and of the
More informationSTUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: REPRODUCTION TESTING
VICH GL22 (SAFETY: REPRODUCTION) Revision 1 May 2004 For implementation at Step 7 STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: REPRODUCTION TESTING Recommended for Implementation
More informationCompany: Richter Pharma AG MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
BASG - Federal Office for Safety in Health Care AGES - Austrian Agency for Health and Food Safety Traisengasse 5, A-1200 Vienna www.basg.gv.at Company: MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT
More informationSales survey of Veterinary Medicinal Products containing Antimicrobials in France
Sales survey of Veterinary Medicinal Products containing Antimicrobials in France - 2009 February 2011 Édition scientifique Sales survey of Veterinary Medicinal Products containing Antimicrobials in France
More informationCOUNCIL REGULATION (EEC) No 2377/90
-W- -- 18. 8. 90 Official Journal of the ~uroiean Communities No L 224/P - - (Acts whose publication is obligatory) COUNCIL REGULATION (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure
More information